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ABSTRACT: Signal transducer and activator of transcription 3
(STAT3) plays important roles in multiple aspects of cancer
aggressiveness including migration, invasion, survival, self-renewal,
angiogenesis, and tumor cell immune evasion by regulating the
expression of multiple downstream target genes. STAT3 is con-
stitutively activated in many malignant tumors and its activation is
associated with high histological grade and advanced cancer stages.
Thus, inhibiting STAT3 promises an attracting strategy for treatment of
advanced and metastatic cancers. Herein, we identiﬁed a STAT3
inhibitor, inS3-54, by targeting the DNA-binding domain of STAT3
using an improved virtual screening strategy. InS3-54 preferentially
suppresses proliferation of cancer over non-cancer cells and inhibits
migration and invasion of malignant cells. Biochemical analyses show
that inS3-54 selectively inhibits STAT3 binding to DNA without aﬀecting the activation and dimerization of STAT3.
Furthermore, inS3-54 inhibits expression of STAT3 downstream target genes and STAT3 binding to chromatin in situ. Thus,
inS3-54 represents a novel probe for development of speciﬁc inhibitors targeting the DNA-binding domain of STAT3 and a
potential therapeutic for cancer treatments.
S ignal transducers and activators of transcription 3(STAT3), a member of the Janus kinase (JAK)/STAT
signaling pathway, is a central transcription factor that is
activated by phosphorylation of a conserved tyrosine residue
(Tyr705) in response to extracellular cytokines and growth
factors.1 Once activated, STAT3 dimerizes and translocates into
the nucleus to induce transcription of downstream target
genes.2 Overexpression and/or constitutive activation of
STAT3 has been detected in a number of human malignancies
including lung and breast cancers.3−5 Subcutaneous injection of
cells harboring constitutively activated STAT3 (STAT3c)
resulted in tumor formation.6 STAT3c overexpression in
mouse alveolar type II epithelial cells led to lung inﬂammation
and consequently spontaneous lung bronchoalveolar adeno-
carcinoma.7 Furthermore, inhibition of STAT3 expression
using antisense oligonucleotides signiﬁcantly impaired the
growth of human and mouse nucleophosmin-anaplastic
lymphoma kinase tumors in xenograft models.8 Thus, STAT3
is an attractive target for anticancer drug discovery.9
Various STAT3 inhibitors have been identiﬁed in the
past10−12 including peptidomimetics13,14 and small molecule
compounds designed from the peptidomimetics15 or via high-
throughput16,17 and virtual screening.18,19 Some of these
inhibitors suppressed tumor growth in vivo.20 Most of these
STAT3 inhibitors were designed to target Src Homology 2
(SH2) domain, where the pTyr705 residue binds for activation
and dimerization, which may not be able to inhibit STAT3
completely considering that monomeric21,22 and unphosphory-
lated dimeric23 STAT3 may also be functional. Thus, inhibiting
the DNA-binding activity of STAT3 regardless of its
phosphorylation and dimerization status may represent a better
approach. However, disrupting protein−DNA interactions with
small molecules targeting DNA-binding domains (DBDs) of
transcription factors is challenging due to potentially limited
selectivity.24,25
In this study, we demonstrate that inhibition of STAT3
function by targeting its DBD is a viable approach using an
improved in-silico screening of a virtual compound database in
combination with biochemical and cell biology analyses. We
identiﬁed a small molecule compound that selectively inhibits
the DNA-binding activity of STAT3 and expression of STAT3
downstream target genes and suppresses cancer cell prolifer-
ation, migration, and invasion. Together, we conclude that the
DBD of STAT3 can be targeted for drug discovery.
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■ RESULTS AND DISCUSSION
Identiﬁcation of a STAT3 Inhibitor Targeting Its DBD.
To identify compounds that can directly block the interaction
between STAT3 and its DNA substrate, we ﬁrst examined the
crystal structure of STAT3β-complexed with DNA and
performed virtual docking of approximately 200,000 com-
pounds to the DBD (Figure 1A). Top-scoring compounds with
phosphate groups functioning similarly as phosphates in DNA
were eliminated due to their potential inability to permeate into
cells. The remaining 1000 top-scoring compounds were then
docked onto the DBD of STAT1 to eliminate compounds that
also bind to STAT1. The ﬁnal list was shortened to 100
potentially speciﬁc candidates.
Of these 100 structurally diversiﬁed compounds, 57 chemical
samples were obtained and tested for their ability to inhibit
STAT3-dependent luciferase reporter expression in MDA-MB-
231 cells. One of the compounds, no. 54, exhibited signiﬁcant
inhibitory activity (Figure 1B) in a dose- and time-dependent
manner (Supplemental Figure S1A,B) with an IC50 of 13.8 ±
0.4 μM and the time required for 50% inhibition at 29.2 ± 4.7
h. This compound, 4-[(3E)-3-[(4-nitrophenyl)-methylidene]-2-
oxo-5-phenylpyrrol-1-yl] benzoic acid (Figure 1C), was named
inS3-54 and used to search the PubChem database of high-
throughput screening for STAT3 inhibitors. No compound
with the same structure was found.
To conﬁrm the activity of the compound using resupplied
material, to eliminate any issues of using a single stable clone
harboring the reporter gene, and to ensure that inS3-54 is not
cell-line-speciﬁc, we tested newly synthesized inS3-54 using
H1299 cells transiently transfected with the STAT3-driven
luciferase reporter gene. Figure 1D shows that a new batch of
inS3-54 also signiﬁcantly inhibits STAT3-dependent luciferase
reporter expression in H1299 cells harboring transient reporter
construct. Thus, the activity of inS3-54 is not derived from
potential contamination in the original supply and is not
dependent on cell line or transfection method used.
Furthermore, inS3-54 did not inhibit the reporter expression
driven by a p27 promoter26 without STAT3-binding site
(Supplemental Figure S1C), suggesting that inS3-54 inhibition
of reporter expression is unlikely due to nonspeciﬁc eﬀect on
the reporter gene or due to cell death induced by inS3-54.
Together, these observations suggest that inS3-54 is a good
chemical probe.27
Figure 1. Schematic diagram and identiﬁcation of inS3-54 by virtual screening. (A) DNA-STAT3 complex structure (PDB code: 1BG1). The red
box shows the site for docking in one of the STAT3 subunits. (B) Luciferase activity assay of MDA-MB-231 cells harboring stable STAT3-dependent
luciferase reporter following treatment with DMSO control or 20 μM compounds for 48 h. (C) Structure of inS3-54. (D) Luciferase activity assay of
H1299 cells transiently transfected with STAT3-dependent luciferase reporter following treatment with DMSO control or 20 μM inS3-54 for 48 h.
(E) Simulated average complex structure of inS3-54 in the DBD of STAT3. (F, G) Molecular surface of STAT3 (F) and STAT1 (G) complexed
with inS3-54 from MD simulation with orientation shown in gold for STAT3 and pink for STAT1. Molecular surface is colored with gray for carbon,
blue for nitrogen, red for oxygen, and yellow for sulfur. (**p < 0.01)
Table 1. inS3-54 Binding Free Energies and Energy Components in STAT1 and STAT3
ΔEsolute ± SE (kcal/mol) ΔGsolv ± SE (kcal/mol)
ΔEele ΔEvdw ΔGes ΔGnes ΔEtot_ele ± SE (kcal/mol) ΔGbind ± SE (kcal/mol)
STAT1 −139.6 ± 3.4 −23.1 ± 1.0 149.6 ± 2.4 −4.0 ± 0.1 10.1 ± 0.4 −17.1 ± 1.0
STAT3 −144.3 ± 4.4 −27.5 ± 0.9 148.0 ± 2.8 −4.6 ± 0.1 3.6 ± 0.8 −28.4 ± 0.9
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InS3-54 Selectively Inhibits the DNA-Binding Activity
of STAT3. To determine the selectivity of inS3-54, we ﬁrst
performed molecular dynamics (MD) simulation and general-
ized born surface area (GBSA) analyses for the binding free
energy (ΔGbind) of inS3-54 docked in the DBD of STAT3 and
STAT1. Table 1 shows that both STAT molecules have
favorable electrostatic (ΔEele) and van der Waals (ΔEvdw)
interaction energy, although they are more favorable for STAT3
than STAT1. The energy from solvation (ΔGsolv) reverses these
favorable energies for both proteins. However, the reversal
eﬀect is less for STAT3 than for STAT1. Consequently, the
total ΔGbind is much more favorable for STAT3 (−28.4 kcal/
mol) than STAT1 (−17.1 kcal/mol). Considering the omitted
Figure 2. InS3-54 inhibits the DNA-binding activity of STAT3 but not STAT1. The eﬀect of inS3-54 on the DNA binding activity of STAT3 (A)
and STAT1 (B) was determined using EMSA and [32P]-labeled double strand DNA probe and whole cell lysate from H1299 cells transiently
transfected with FLAG-STAT3c or STAT1 cDNA.
Figure 3. Binding of inS3-54 to STAT3. (A) Ectopic overexpression of FLAG-STAT3 (S3) in H1299 cells. Vec = vector control. (B) Pull-down
assay of STAT3 from lysate of FLAG-STAT3-transfected H1299 cells using EAH-Sepharose 4B-conjugated without (vehicle control, VC) or with
inS3-54 (inS3). Pull-down materials were separated using SDS-PAGE and Western blot analysis probed with STAT3 antibody (IB) or stained with
silver (SS). (C) Pull-down materials using EAH-Sepharose 4B-conjugated without (VC) or with inS3-54 (inS3) were treated at room temperature
(RT) or by boiling before separation on SDS-PAGE for Western analysis. (D) Competition of STAT3-binding to inS3-54-conjugated EAH-
Sepharose 4B by excess free inS3-54 (inS3), an irrelevant compound (IC) control, or vehicle control (VC). (E) Elution of STAT3 bound to inS3-54-
conjugated EAH-Sepharose 4B by inS3-54 (inS3), an irrelevant compound (IC) control, or vehicle control (VC). (F) Pull-down assay of puriﬁed
STAT3 with input shown by silver staining (SS).
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entropy term, which is always unfavorable, inS3-54 may not
bind to STAT1 or have a very low aﬃnity.
Examination of the average simulated structures (Figure 1E)
of inS3-54-bound STAT3 and STAT1 agrees with the
calculated ΔGbind. Contribution of hydrophobic interactions
from STAT3 to inS3-54 binding is mainly from residues
Met331, Val343, Met420, Ile467, and Met470. The amino
groups of Lys340 and Asn466 stabilize the carboxyl group of
inS3-54 by favorable electrostatic interactions. However, the
orientation of inS3-54 docked in STAT1 (Figure 1G) is very
diﬀerent (Figure 1F). This binding mode in STAT1 likely
results in an unfavorable ΔGbind. Forcing inS3-54 to adopt the
same orientation in STAT1 as in STAT3 results in clashes
between inS3-54 and residues Pro326 and Thr327 of STAT1
(Figure 1G). Thus, it is unlikely that inS3-54 can bind to
STAT1.
To verify the above ﬁndings and to determine the inS3-54
inhibition of the DNA-binding activity of STAT3 or STAT1,
we performed electrophoretic mobility shift assay (EMSA)
using a [32P]-labeled probe and H1299 cells transiently
transfected with FLAG-STAT3c or STAT1. As shown in
Figure 2A, the speciﬁc binding of the DNA probe to STAT3
was demonstrated using supershift and competition analyses.
InS3-54 inhibited the DNA-binding activity of STAT3 in a
dose-dependent manner with an IC50 of ∼20 μM, which is
consistent with the cell-based reporter assay (see above). The
speciﬁc binding of DNA probe to STAT1 as shown by
interference of binding using cold probe and STAT1 antibody
that is known to interfere DNA-binding activity of STAT1,28,29
however, was not aﬀected by inS3-54 up to 300 μM (Figure
2B). Thus, inS3-54 selectively inhibits the DNA-binding activity
of STAT3 over STAT1.
Binding of inS3-54 to STAT3. To verify that inS3-54 can
bind to STAT3, we took advantage of the carboxyl group of
inS3-54 and conjugated it to EAH Sepharose. InS3-54-
conjugated beads were then used to pull down STAT3 from
FLAG-STAT3-transfected H1299 cells followed by Western
blot analysis or silver staining. Figure 3A shows the expression
of FLAG-STAT3. Figure 3B shows that inS3-54-conjugated
beads successfully pull down STAT3, whereas the vehicle
control beads do not. It is noteworthy that STAT3 bound to
the inS3-54-conjugated beads was solubilized equivalently well
by SDS sample buﬀer with or without heating (Figure 3C).
Furthermore, pretreatment of cell lysates using excess free inS3-
54, but not vehicle or an irrelevant compound, inhibited
STAT3 pull-down by inS3-54-conjugated beads (Figure 3D).
STAT3 bound to the inS3-54-conjugated beads could be eluted
by excess inS3-54 but not by vehicle control or the irrelevant
compound (Figure 3E). Finally, inS3-54-conjugated beads
could also pull down puriﬁed STAT3 in the absence of other
proteins (Figure 3F). On the basis of these ﬁndings, we
conclude that inS3-54 can bind directly and noncovalently to
STAT3.
InS3-54 Is Not an Alkylating Agent. Recently, it was
found that Cys468 in DBD of STAT3 can be alkylated by and
covalently linked to a small molecule inhibitor, C48.30 The
ﬁndings from pull-down assays show that inS3-54 can bind, but
unlikely covalently, to any residues (e.g., Cys or Lys) in STAT3,
suggesting that inS3-54 did not alkylate STAT3. To further
eliminate the possibility that inS3-54 has alkylating activity, we
performed luminescence-based glutathione alkylation assay. As
shown in Supplemental Figure S2, inS3-54, unlike the known
alkylating agent iodoacetamide, did not signiﬁcantly reduce
glutathione level in both A549 and MDA-MB-231 cells. Thus,
inS3-54 unlikely possesses any alkylating activity.
InS3-54 Does Not Inhibit STAT3 Dimerization. The
SH2 domain of STAT3 has previously been shown to be
susceptible for targeting (see beginning paragraphs). To
eliminate the possibility that inS3-54 works by oﬀ-targeting to
the SH2 domain, we tested if inS3-54 inhibits STAT3
dimerization using FLAG-STAT3c, which forms spontaneous
homodimers via formation of intermolecular disulﬁde bond.6
Supplemental Figure S3A shows that STAT3c is successfully
expressed in H1299 cells in both dimeric and monomeric forms
separated by nonreducing SDS-PAGE. However, inS3-54 had
no eﬀect on production of dimeric STAT3c separated using
nonreducing SDS-PAGE or non-denaturing PAGE (Supple-
mental Figure S3B) while S3I-201, a STAT3 inhibitor that
binds to the SH2 domain,19 inhibited STAT3c dimerization
(Supplemental Figure S3B).
To conﬁrm this observation, we performed a co-immuno-
precipitation analysis of HA- and FLAG-tagged STAT3.
Supplemental Figure S3C shows that HA- and FLAG-tagged
STAT3 can be co-expressed and co-immunoprecipitated
successfully in H1299 cells. InS3-54 had no eﬀect, while S3I-
201 inhibited the co-immunoprecipitation between HA- and
FLAG-tagged STAT3 (Supplemental Figure S3D). Thus, inS3-
54 likely does not inhibit STAT3 dimerization or bind to the
SH2 domain.
InS3-54 Favorably Inhibits Cancer Cell Survival by
Inducing Apoptosis. Next, we determined whether inS3-54
inhibits growth and survival of cancer cells using two lung
(A549 and H1299) and two breast (MDA-MB-231 and MDA-
MB-468) cancer cell lines, as well as non-cancer lung ﬁbroblast
(IMR90) and mammary epithelial cell line (MCF10A1). As
shown in Figure 4A, all cancer cells had constitutively activated
STAT3 as assessed by its phosphorylation status at Tyr705,
compared to the non-cancer cells, consistent with previous
ﬁndings.4,18,19 The cancer cells are also more sensitive to inS3-
54 with IC50’s signiﬁcant lower than those of the non-cancer
cells (3.2−5.4 vs 10−12 μM, see Figure 4B,C). This ﬁnding of
∼2−4-fold diﬀerence in IC50 is consistent with the diﬀerential
status of constitutively activated STAT3 between cancer and
non-cancer cells and suggests that there may be a therapeutic
window for inS3-54.
To determine if apoptosis contributes to inS3-54 suppression
of cancer cell survival, we performed apoptosis analysis of
exponentially growing cells using ELISA following inS3-54
treatment for 72 h. As shown in Figure 4D, inS3-54 induced
apoptosis of both A549 and MDA-MB-231 cells in a dose-
dependent manner. InS3-54 treatment also induced cleavage of
PARP in breast cancer cell line MDA-MB-468 (data not
shown), a target of activated caspases during execution of
apoptosis, conﬁrming that 72-h treatments with inS3-54 induce
apoptosis.
InS3-54 Inhibits Cancer Cell Migration and Invasion.
STAT3 also plays an important role in controlling cell
migration and invasion by regulating the expression of genes
such as MMP-1, -2, -9, -10, Twist, and VEGF important for
these cellular processes.31−36 To determine if inS3-54 inhibits
migration and invasion, we ﬁrst performed a wound-healing
assay using A549 and MDA-MB-231 cells. Figure 5A,B shows
that inS3-54 inhibits migration of both A549 and MDA-MB-
231 cells in dose- and time-dependent manners. At 24 h, about
57% and 95% of wounds were healed in the control vehicle-
treated A549 and MDA-MB-231 cells, respectively. However,
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only 42% and 77% of the wounds were healed for these cells at
24 h following treatment with 10 μM inS3-54. The wound
healing further reduced to 23% and 39% after treatment with
20 μM inS3-54.
We then performed a Matrigel invasion assay. Figure 5C,D
shows that both A549 and MDA-MB-231 cells exhibit
signiﬁcantly decreased invasion in the presence of inS3-54
than vehicle. At 6 h of treatment with 10 and 20 μM inS3-54,
the invasion was reduced to 67% and 49% for A549 cells and to
52% and 24% for MDA-MB-231 cells, respectively. At 24 h of
treatment with 10 μM inS3-54, the invasion of A549 and MDA-
MB-231 cells was about 71% and 24% of controls, respectively.
These numbers were further reduced to 33% and 5% in the
presence of 20 μM inS3-54.
Although we used 100% conﬂuent cells and short time
incubation in the above assays, inhibition of proliferation may
still contribute to the observed outcomes. To eliminate this
possibility, we analyzed cell proliferation and apoptosis under
the same condition as wound-healing and Matrigel invasion
assays with conﬂuent cultures and found that treatment with 20
μM inS3-54 for 24 h had no signiﬁcant eﬀect on proliferation
(Supplemental Figure S4A) and apoptosis (Supplemental
Figure S4B) of conﬂuent A549 cells, although it decreased
the proliferation and increased apoptosis of MDA-MB-231
cells. However, 10 μM inS3-54 did not signiﬁcantly decrease
proliferation or increase apoptosis of MDA-MB-231 cells
(Supplemental Figure S4), under which condition it signiﬁ-
cantly reduced the migration and invasion activity of these cells
(Figure 5). Furthermore, no apoptosis was observed at 6 h of
treatment with 20 μM inS3-54. Thus, we conclude that inS3-54
inhibition of migration and invasion is unlikely due to its eﬀect
on apoptosis and cell proliferation.
InS3-54 Inhibits STAT3 Downstream Target Gene
Expression and STAT3 Binding to Genomic DNA. To
validate inS3-54 eﬀect on STAT3 in cells, we determined the
expression of STAT3 downstream target genes. Figure 6A
shows that the expression of cyclin D1, survivin, VEGF, MMP-
2, MMP-9, and Twist are all decreased following inS3-54
treatment in both A549 and MDA-MB-231cell lines at protein
level. This observation was conﬁrmed by quantitative RT-PCR
analysis of mRNAs (Supplemental Figure S5).
InS3-54, however, had no eﬀect on the level of total STAT3
or basal level of Tyr705-phosphorylated STAT3 (Figure 6A),
indicating that inS3-54 does not aﬀect the expression or
activation of STAT3. To further determine if inS3-54 inhibits
STAT3 activation and phosphorylation, serum-starved A549
cells were pretreated with inS3-54 followed by IL-6 stimulation
and analysis of phosphorylated STAT3. Figure 6B shows that
IL-6 stimulates phosphorylation of Tyr705 of STAT3 and
expression of survivin in serum-starved A549 cells. Pretreat-
ment with inS3-54 had no eﬀect on IL-6-stimulated
phosphorylation of STAT3 but inhibited IL-6 stimulated
expression of survivin. Thus, inS3-54 does not aﬀect IL-6
stimulated phosphorylation/activation of STAT3 but inhibits
STAT3 activity.
The EMSA data (Figure 2) show that inS3-54 inhibits the
DNA-binding activity of STAT3 in vitro. To further
demonstrate that inS3-54 inhibits the DNA-binding activity
of STAT3 in situ, we treated A549 and MDA-MB-231 cells
with inS3-54 followed by isolation of cytosol, soluble nuclear,
and chromatin-bound fractions and determined STAT3 level in
these fractions. Figure 6C shows that STAT3 in the chromatin-
bound fraction decreases while the STAT3 level in soluble
nuclear fraction increases with the increasing concentration of
inS3-54. Furthermore, inS3-54 dramatically decreased the
binding of STAT3 to the promoters of Twist and cyclin D1
as determined using ChIP assay (Figure 6D). Taken together,
we conclude that inS3-54 inhibits STAT3 binding to
endogenous promoters on genomic DNA, resulting in reduced
transcription of its downstream target genes.
In summary, with the aid of structure-based virtual screening,
we successfully identiﬁed a human STAT3 inhibitor targeting
its DBD. This study represents one of the ﬁrst successful
attempts in targeting the prevailing “undruggable” DBD of
transcription factors. InS3-54 is selective to STAT3 over
STAT1 as demonstrated using EMSA. In-silico analysis shows
that inS3-54 could not bind to STAT1 due to physical
hindrance from residue Pro326 and Thr327 and, thus, has a
much lower aﬃnity to STAT1. The ﬁnding that inS3-54 does
not inhibit the promoter activity of p27 is also consistent with
its selectivity. Finally, the less cytotoxic eﬀect of inS3-54 on
non-cancer compared to cancer cells further conﬁrms that inS3-
54 is likely selective to STAT3.
As expected, inS3-54 inhibits the DNA-binding activity of
STAT3 both in vitro and in situ. Although inS3-54 likely binds
to STAT3 and is selective for STAT3 over STAT1, it is
unknown if it is speciﬁc only to STAT3. In fact, other proteins
were pulled down together with STAT3 by inS3-54-conjugated
beads. While these proteins may have been pulled down
Figure 4. InS3-54 inhibits cancer cell proliferation. (A) Level of
STAT3 expression and activation in diﬀerent cells. Actin was used as a
loading control. (B, C) Cytotoxicity assay. IC50 of inS3-54 for each cell
line was derived, and dose−response curves were created using
PrismPad program. (D) Apoptosis assay of exponentially growing
A549 and MDA-MB-231 cells. (**p < 0.01; *p < 0.05)
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indirectly by interacting with STAT3, they may also interact
directly with inS3-54. More studies are needed to diﬀerentiate
these possibilities. Furthermore, since inS3-54 does not inhibit
STAT3 activation and phosphorylation and unlikely binds to
the SH2 domain, it likely binds to the DBD of STAT3 and
directly inhibits its DNA-binding activity, although more
studies are needed to show its direct binding to the DBD of
STAT3.
It is noteworthy that inS3-54 has an IC50 of ∼20 μM in
inhibiting DNA-binding activity in the EMSA assay and an IC50
of ∼15.8 μM in the luciferase reporter assay. However, the IC50
of inS3-54 in the cytotoxicity assay ranges from ∼3.2−5.4 μM
in cancer to ∼10−12 μM in non-cancer cells. Currently, it is
unknown why inS3-54 is more eﬀective in inhibiting cell
survival than inhibiting DNA binding and luciferase reporter
expression. However, inS3-54 may have oﬀ-target eﬀects that
can impact on cell survival, making it more eﬀective in
suppressing cancer cell survival. Future studies of transcriptome
change due to inS3-54 inhibition of gene expression may help
address the potential oﬀ-target eﬀect.
■ METHODS
Structure-Based Virtual Screening. The DNA in the DBD of
STAT3β-DNA complex structure (PDB code: 1BG1) was removed,
and the protein chain was prepared for docking. The DNA-binding
groove consisting of residues 329−332, 340−346, 406−412, and 465−
468 was chosen as the targeting site for docking (Figure 1A).
Molecular surface was calculated using the DMS (Distributed
Molecular Surface) program. Partial charges and protons were added
to the protein by the UCSF Chimera Dock Prep module.37 In-silico
dock screening of 200,000 compounds from the ChemDiv library was
performed using the UCSF DOCK 6.0 program.38 The docking of
each compound was ﬁrst scored with the DOCK GRID scoring
function.39 The top-scoring 1000 compounds were analyzed again and
rescored using the AMBER scoring function of the DOCK 6.0
package.40
To improve in-silico screening for a STAT3-selective inhibitor, the
top-scoring compounds from above screening were then docked onto
the DBD of STAT1 (PDB code: 1BF5) in the same way as to STAT3.
Both STAT3 and STAT1 bind to very similar 9-bp core consensus
sequences with minor diﬀerences in ﬂanking sequences.41 However,
there are minor diﬀerences in DBD between STAT3 and STAT1 (e.g.,
Met331, Thr412, Ile467 in STAT3 replace Thr327, Gln408, and
Figure 5. InS3-54 inhibits cancer cell migration and invasion. (A, B) Eﬀect of inS3-54 on migration. Panel B shows quantiﬁcation analysis of wound
healing assay from triplicate measurements of three independent experiments shown in panel A. (C, D) Eﬀect of inS3-54 on cell invasion. Panel D
shows quantiﬁcation of invasion from measurement of 10 random views each of three independent experiments shown in panel C. (***p < 0.001;
**p < 0.01; *p < 0.05)
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Val461 in STAT1, respectively), which may help distinguish selective
compound inhibitors. Compounds that scored well with STAT1 were
eliminated, and the remaining ones were clustered using the MOE
(Molecular Operating Environment) program and visually examined
using the UCSF Chimera ViewDock function. A ﬁnal 100 compounds
were selected on the basis of the combination of GRID and AMBER
score, drug likeness (Lipinski’s rule of ﬁve), and consideration of
maximizing compounds from diﬀerent clusters.
Molecular Dynamics Simulation and Calculation of Binding
Free Energy (ΔGbind). ΔGbind determinations of inS3-54 to STAT3
and STAT1 were performed by 3-ns MD simulations followed by
energy analysis using GBSA method42 as we previously described.43
Brieﬂy, a total of 20 snapshots were collected from the production
trajectory for molecular mechanic (MM)-GBSA free energy
calculations using the formula ΔGbind= Gcomplex − GSTAT − GinS3‑54,
where G = Gsolute + Gsolvent.
STAT3-Dependent Luciferase Assay. In this and all following
assays, candidate compounds were dissolved and completely soluble in
DMSO at 20 mM as a stock solution. MDA-MB-231 stably transfected
or H1299 cells transiently transfected with STAT3-dependent
luciferase reporter were incubated with candidate compounds at
diﬀerent concentrations for various times, and luciferase activity was
measured using a luciferase assay kit (Promega), following
manufacturer’s instructions. The ﬁnal DMSO concentration in this
and following assays was 0.1% (v/v).
Cytotoxicity and Apoptosis Assay. Cytotoxicity of inS3-54 was
determined using a sulphorhodamine colorimetric assay as described
previously.44 Photometric enzyme immunoassay using a Cell Death
Detection ELISA Plus kit (Roche Diagnostics, Indianapolis, IN) was
performed for quantitative in vitro determination of cytoplasmic
histone-associated DNA fragments and apoptosis as previously
described.44
Electrophoretic Mobility Shift Assay (EMSA). H1299 cells were
transiently transfected with FLAG-tagged STAT3c or STAT1
expression construct. Forty-eight hours following transfection, cells
were harvested and lysed with 3 cycles of freeze and thaw. Then 10−
20 μg of lysate was mixed with 2 μg of poly(dI-dC), 1 μg BSA in
binding buﬀer (10 mM HEPES, pH 7.9, 50 mM KCl, 10% glycerol, 0.2
mg mL−1 BSA, 1 mM DTT, and 0.2 mM PMSF), and 4 × 104 cpm
[32P]-labeled SIE probe. The mixture was incubated for 20 min at RT
and separated on 6% non-denaturing PAGE. The signal was detected
by autoradiography. For supershift and competition, 2 μL of speciﬁc
antibodies against STAT3 or STAT1 or 100-fold cold SIE probe (5′-
AGCTTCATTTCCCGTAAATCCCTA-3′) was added to the reac-
tion mixture and incubated for 30 min before adding labeled SIE
probe. To determine the eﬀect of inS3-54 on STAT3 or STAT1
binding to SIE probe, inS3-54 was ﬁrst diluted with DMSO, and equal
volume of diluted inS3-54 was added to the reaction mixture followed
by incubation at RT for 30 min before incubating with the labeled SIE
probe.
Conjugation of inS3-54 and Pull-down Assay. EAH-Sepharose
4B containing free amino groups with 11-atom spacer arms was used
to couple inS3-54 with the carbodiimide coupling method according to
manufacturer’s instructions. Control EAH-Sepharose was prepared
exactly the same way without inS3-54. Since inS4−54 is orange in
color, the conjugation of inS3-54 to EAH-Sepharose was veriﬁed by
monitoring the color change of the EAH beads.
For the pull-down assay, inS3-54-conjugated and control beads
equilibrated with binding buﬀer (10 mM MES/NaOH, pH 6.5, 150
mM NaCl, 2 mM MgCl2, 2 mM CaCl2, 5 mM KCl, 0.5% NP-40) were
blocked with 10% milk in the binding buﬀer containing 0.2 mM PMSF
and protease inhibitor cocktails followed by incubation with 60 μg of
lysate of H1299 cells harboring FLAG-STAT3 or 1 μg of puriﬁed
STAT3 (Sigma) at RT for 1 h. The unbound proteins were removed
by washing 7 times, and the bound proteins were separated by SDS-
PAGE followed by analysis using Western blot or silver staining. For
competition, cell lysate was preincubated with 10 μM inS3-54, DMSO
vehicle or an irrelevant compound control at RT for 1 h prior to the
pull-down assay. For elution, following binding STAT3 using inS3-54-
conjugated beads as described above, the protein−bead complex were
eluted using vehicle control, 300 μM inS3-54 or the irrelevant
compound in binding buﬀer containing 20% DMSO.
Migration and Invasion Assay. For the wound-healing assay, 1 ×
105 cells per well were plated in 6-well plates followed by introduction
of a wound and monitoring of the healing process of the wound over a
24-h period. The healing of the wound was determined by measuring
the remaining gap between two migrating edges at diﬀerent times. Cell
invasion assay was performed using Matrigel-coated Boyden Chambers
(BD Biosciences) according to manufacturer’s instructions. At
diﬀerent times, invading cells were stained with crystal violate and
counted.
Subcellular Fractionation. Subcellular fractionation was per-
formed as previously described.45 Brieﬂy, cells were lysed in 10 mM
HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10%
glycerol, 1% Triton X-100, 1 mM DTT, 10 μM leupeptin, and
protease inhibitor cocktail and centrifuged at 4,200g for 5 min to
collect supernatant as cytosolic fraction. The pellet (nuclei) was
resuspended in 3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, 10 μM
leupeptin, protease inhibitor cocktail and incubated on ice for 30 min
followed by centrifugation at 5,000g for 5 min. The supernatant was
collected as soluble nuclear fraction. The pellet was resuspended in 50
mM Tris/HCl, pH7.4, 150 mM NaCl, 0.5% NP-50, 5 mM EDTA, 50
mM NaF, 1 mM Na3VO4, 1% SDS, 1 mM DTT, 10 μM leupeptin,
protease inhibitor cocktail and sonicated to release proteins from
chromatins.
ChIP Assay. H1299 cells were ﬁrst treated with 20 μM inS3-54
followed by treatment with 1% formaldehyde for 10 min and ChIP
assay using a kit (EMD Millipore). Immunoprecipitated DNA was
then subjected to PCR with primer pairs speciﬁc for promoters of
cyclin D1 (5′-AACTTGCACAGGGGTTGTGT-3′/5′-GAGACCAC-
Figure 6. InS3-54 inhibits the expression of STAT3 downstream target
genes and STAT3 binding to chromatin. (A) Eﬀect of inS3-54 on the
expression of STAT3 downstream target genes in A549 and MDA-
MB-231 cells. (B) Inhibition of IL-6 (25 ng/mL) stimulated STAT3
activation in serum-starved A549 cells. Actin was used as a loading
control. (C, D) InS3-54 inhibition of STAT3 binding to chromatin in
situ as determined using subcellular fractionation and Western blot
analysis (C) or ChIP assay of Twist and cyclin D1 promoters (D).
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GAGAAGGGGTGACTG-3′) and twist (5′-AGTCTCCTCCGA-
CCGCTTCCTG-3′/5′-CTCCGTGCAGGCGGAAAGTTTGG-3′).
Quantitative RT-PCR. Quantitative RT-PCR analysis was
performed using primers shown in Supplemental Table S1 as
previously described.46 The threshold cycles (Ct) were determined
and normalized against that of GAPDH internal control. The relative
mRNA levels were shown as the value of 2−ΔCt.
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